Company intelligence / Profile preview

Regenex Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Regenerex’s products have demonstrated high rates of complete closure for chronic wounds within 90 days in multiple clinical evaluations. Their approach focuses on modulating the cellular environment of chronic wounds using their proprietary QBx™ technology.

Therapeutic areas: EndocrinologyDermatology
Modalities: Topical biologic dressings and proprietary wound healing formulas using QBx™ technology
Industry: Biotech

Drug pipeline

1 asset

estradiol

Commercial

Indications: Hormone therapy

Beyond the preview

Go deeper on Regenex Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenex Pharmaceutical.

Explore the full profile